CD8A and type 1 diabetes mellitus: Therefore, we used CRISPR/Cas9 to knockout (KO) the endogenous TCRα in engineered IGRP-reactive CD8+ T cells, with the goal of more effectively recapitulating autoreactive CD8+ T cell function in T1D.